bevacizumab may differentially improve survival for patients with the proliferative and mesenchymal...

25
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Upload: amy-armstrong

Post on 17-Jan-2016

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 2: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Disclosure

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 3: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 3

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 4: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

ICON7/AGO-OVAR 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 5: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

ICON7/AGO-OVAR 11 <br />PFS and OS

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 6: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

ICON7/AGO-OVAR 11 <br />PFS and OS<br />High risk group suboptimal stage III and stage IV

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 7: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Molecular Classification of HGS Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 8: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 8

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 9: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 9

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 10: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 10

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 11: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 12: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 12

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 13: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Overall (n=359)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 14: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />High risk for progression (n=119)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 15: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype (n=96)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 16: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype (n=68)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 17: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Differentiated Subtype (n=73)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 18: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Immunoreactive Subtype (n=122)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 19: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Slide 19

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 20: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype HGS (n=63)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 21: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype HGS (n=43)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 22: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 23: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Conclusion

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 24: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Acknowledgements

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 25: Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting